Pharmacy Coupons May Cost More Than They Save for Insured Patients

Problem-solution framing that emphasizes complexity and potential harms to insured patients, positioning manufacturers and insurers as adversarial forces with patients caught between them.

Not applicable - this concerns U.S. pharmaceutical industry practices and insurance regulations, not international relations.

Insured patients face reduced coupon benefits due to copay accumulators preventing savings from counting toward deductibles, while uninsured patients benefit most. Overall affordability concerns persist despite coupon availability, potentially delaying medication adherence.

Regulators may need to address copay accumulator practices, potentially through legislation limiting their use or requiring transparency. CMS and state insurance commissioners may investigate whether these practices violate consumer protection standards or constitute unfair insurance practices.